FDA 483 - Macleods Pharmaceuticals Limited - August 23, 2024

Macleods Pharmaceuticals Limited, a drug manufacturer in Pithampur, Madhya Pradesh, India, received an FDA Form 483 following an inspection from August 20-23, 2024. The document outlines several significant observations regarding the company's quality systems. A primary concern was the failure to thoroughly investigate unexplained discrepancies, specifically numerous recurrent gasket leakages in equipment used for U.S. marketed drug products since January 2022. The firm lacked detailed root cause analysis, identification of specific damage, implementation of preventive actions, and quality unit trending for these engineering issues. Another observation noted deficiencies in handling drug product complaints. An adverse event complaint, involving a "Lack of Effect" and a "Product Quality Complaint," was not appropriately triaged or investigated by the corporate quality assurance department or the manufacturing site, contrary to internal procedures. Lastly, the inspection found that the responsibilities and procedures for the quality control unit were not adequately defined in writing. This was evident in the absence of quality unit oversight for critical alarms from the water storage and distribution system, essential for cleaning manufacturing equipment. Macleods Pharmaceuticals Limited is expected to address these observations by implementing robust corrective and preventive actions to ensure compliance with good manufacturing practices.